Your browser doesn't support javascript.
loading
Validation of the IPF-specific version of St. George's Respiratory Questionnaire.
Prior, Thomas Skovhus; Hoyer, Nils; Shaker, Saher Burhan; Davidsen, Jesper Rømhild; Yorke, Janelle; Hilberg, Ole; Bendstrup, Elisabeth.
Afiliação
  • Prior TS; Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark. thbjer@rm.dk.
  • Hoyer N; Department of Respiratory Medicine, Herlev-Gentofte University Hospital, Copenhagen, Denmark.
  • Shaker SB; Department of Respiratory Medicine, Herlev-Gentofte University Hospital, Copenhagen, Denmark.
  • Davidsen JR; Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark.
  • Yorke J; University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.
  • Hilberg O; Department of Respiratory Medicine, Vejle Hospital, Vejle, Denmark.
  • Bendstrup E; Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.
Respir Res ; 20(1): 199, 2019 Aug 28.
Article em En | MEDLINE | ID: mdl-31462235
ABSTRACT

BACKGROUND:

Patients with idiopathic pulmonary fibrosis (IPF) have impaired health-related quality of life (HRQL). To measure HRQL, an IPF-specific version of the St. George's Respiratory Questionnaire (SGRQ-I) was developed, but not sufficiently validated. This study aimed to assess the validity (i.a. known-groups validity and concurrent validity) and test-retest reliability of SGRQ-I in IPF patients with different disease durations.

METHODS:

Patients with IPF were consecutively recruited and completed SGRQ, SGRQ-I, King's Brief Interstitial Lung Disease questionnaire (K-BILD), University of California, San Diego Shortness of Breath Questionnaire (SOBQ) and Short Form-36 (SF-36) along with pulmonary function tests and a 6-min walk test (6MWT) at baseline. After two weeks, SGRQ-I and Global Rating of Change Scales (GRCS) were completed.

RESULTS:

At baseline and after two weeks, 150 and 134 patients completed the questionnaires, respectively. The internal consistency of SGRQ-I was high (Cronbach's α = 0.92). Good concurrent validity was demonstrated by high intraclass correlation coefficients (ICC = 0.97), Bland-Altman plots and moderate to strong correlations to K-BILD, SOBQ and SF-36 (r = - 0.46 to 0.80). High ICC (0.92) and a Bland-Altman plot indicated good test-retest reliability. SGRQ-I was good at discriminating between patients with different stages of disease (Δscore > 18.1, effect sizes > 0.10). Validity was similar across groups of different disease duration.

CONCLUSIONS:

SGRQ-I proved to be valid at distinguishing between different disease severities, valid compared to other HRQL instruments, applicable across different disease durations and reliable upon repetition. SGRQ-I is a valid option for measuring HRQL in patients with IPF. TRIAL REGISTRATION The study was registered at clinicaltrials.org ( NCT02818712 ) on 15 June 2016.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Qualidade de Vida / Tradução / Inquéritos e Questionários / Fibrose Pulmonar Idiopática Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Respir Res Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Dinamarca

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Qualidade de Vida / Tradução / Inquéritos e Questionários / Fibrose Pulmonar Idiopática Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Respir Res Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Dinamarca